Immediate myeloid depot for SARS-CoV-2 in the human lung

人肺中SARS-CoV-2的直接髓系储存库

阅读:2
作者:Mélia Magnen ,Ran You ,Arjun A Rao ,Ryan T Davis ,Lauren Rodriguez ,Olivier Bernard ,Camille R Simoneau ,Lisiena Hysenaj ,Kenneth H Hu ,Mazharul Maishan ,Catharina Conrad ,Oghenekevwe M Gbenedio ,Bushra Samad ,The Ucsf Comet Consortium ,Christina Love ,Prescott G Woodruff ,David J Erle ,Carolyn M Hendrickson ,Carolyn S Calfee ,Michael A Matthay ,Jeroen P Roose ,Anita Sil ,Melanie Ott ,Charles R Langelier ,Matthew F Krummel ,Mark R Looney

Abstract

In the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, epithelial populations in the distal lung expressing Angiotensin-converting enzyme 2 (ACE2) are infrequent, and therefore, the model of viral expansion and immune cell engagement remains incompletely understood. Using human lungs to investigate early host-viral pathogenesis, we found that SARS-CoV-2 had a rapid and specific tropism for myeloid populations. Human alveolar macrophages (AMs) reliably expressed ACE2 allowing both spike-ACE2-dependent viral entry and infection. In contrast to Influenza A virus, SARS-CoV-2 infection of AMs was productive, amplifying viral titers. While AMs generated new viruses, the interferon responses to SARS-CoV-2 were muted, hiding the viral dissemination from specific antiviral immune responses. The reliable and veiled viral depot in myeloid cells in the very early phases of SARS-CoV-2 infection of human lungs enables viral expansion in the distal lung and potentially licenses subsequent immune pathologies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。